Profitability:
Q1 2026 delivered positive GAAP net income and a healthy adjusted EBITDA margin, reflecting emphasis on mix and efficiency. Management also signaled higher full‑year adjusted EBITDA despite near‑term revenue pressure.
Product Line Growth:
Pharma Direct expanded rapidly and newer condition‑specific subscriptions returned to growth. These offerings are scaling as manufacturer programs and self‑pay pricing gain traction.
Diversified Revenue Streams:
Growth is shifting from legacy prescription transactions toward Pharma Direct and subscriptions. This mix supports margins even if total revenue is flat to slightly down near term.
